Cannakeys

Unlocking the Science of Cannabis

CK Home / N-Arachidonoyl Dopamine (NADA) Cannabinoid Research

N-Arachidonoyl Dopamine (NADA) Cannabinoid Research

N-Arachidonoyl Dopamine (NADA) Research Dashboard

28

Primary Studies

13

Related Studies

41

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind Clinical Trials

0

Clinical Trials

Pre-Clinical Studies

4

Meta-analyses/Reviews

6

Animal Studies

18

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 41 studies associated with N-Arachidonoyl Dopamine (NADA).

Here is a small sampling of N-Arachidonoyl Dopamine (NADA) studies by title:

  • The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice
  • The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review
  • Influence of N-Arachidonoyl Dopamine and N-Docosahexaenoyl Dopamine on the Expression of Neurotrophic Factors in Neuronal Differentiated Cultures of Human Induced Pluripotent Stem Cells under Conditions of Oxidative Stress
  • Neuroprotective and neurotoxic effects of endocannabinoid-like compounds, N-arachidonoyl dopamine and N-docosahexaenoyl dopamine in differentiated cultures of induced pluripotent stem cells derived from patients with Parkinson's disease
  • Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

Components of the N-Arachidonoyl Dopamine (NADA) Research Dashboard

  • Top medical conditions associated with N-Arachidonoyl Dopamine (NADA)
  • Proven effects in clinical trials for N-Arachidonoyl Dopamine (NADA)
  • Receptors associated with N-Arachidonoyl Dopamine (NADA)
  • Individual study details for N-Arachidonoyl Dopamine (NADA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - N-Arachidonoyl Dopamine (NADA)

Description of N-Arachidonoyl Dopamine (NADA)

N-acyldopamines are a group of endocannabinoids of which N-arachidonoyl dopamine (NADA) is one of its most prominent and most studied members.


NADA is present in very low concentrations in various portions of the brain such as the striatum, hippocampus, cerebellum, thalamus, midbrain, and dorsal root ganglia for example.


Additionally a novel class of synthetic anandamide (AEA) analogues were described by a group of Italian researchers (T. Bisogno et al., 2000).

Other Names:

N-Arachidonoyl Dopamine

Arachidonoyl dopamine, N-Arachidonyldopamine, NADA dopamine and others.


IUPAC Name: (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide


Molecular Formula: C28H41NO3


Source–PubChem

N-Arachidonoyl Dopamine (NADA) Properties and Effects

Only Members can view Properties and Effects information. See DEMO page.

N-Arachidonoyl Dopamine (NADA) Receptor Binding

Only Members can view Receptor Binding information. See DEMO page.

Top  

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.